

LiquiMAX CALCIUM - SLR

(ARSENAZO III METHOD)

ORDERING INFORMATION

Ref. No.	Pack Size	Presentation
AVCAL1 - 25	25 x 1 ml	Single Liquid Reagent
AVCAL1 - 50	50 x 1 ml	
AVCAL1 - 100	2 x 50 ml	

INTENDED USE :

LiquiMAX CALCIUM is an in-vitro diagnostic kit for the quantitative determination of calcium in human serum, plasma and urine.

PRODUCT FEATURES:

1. Single Liquid Reagent. Available in mono test packs
2. One step End Point assay
3. Heating and centrifugation of specimen not required.
4. Addition of 8-Hydroxy Quinolene overcomes Magnesium interference.
5. Results correlate with (O-CPC) and Methyl Thymol Blue Methods.
6. Linearity 25 mg/dl.
7. Can be used on any colorimeter, spectrophotometer, discrete semi automated and automated analyzers.

CLINICAL SIGNIFICANCE :

The calcium content of an adult is somewhat over 1 kg (25000 mmol), i.e. about 2% of the body weight. of this, 99% is present as calcium hydroxyapatite in bones and less than 1 % is present in the extraosseous ICS (intracellular space) or ECS (extracellular space). The calcium level in the ECS (approx. 100 mmol) is in dynamic equilibrium with the rapidly exchangeable fraction of bone calcium. Calcium ions affect the contractility of the heart and the skeletal musculature and are essential for the function of the nervous system. In addition, calcium ions play an important role in blood clotting and bone mineralization. In plasma, calcium is bound to a considerable extent to proteins (approx. 40%), 10% is in the form of inorganic complexes and 50% is present as free (ionized) calcium. The body's calcium balance is calcitonin. The test is used for the diagnosis and monitoring of regulated by the parathyroid hormone (PTH), calcitriol (CT) and hypocalcemia (calcium deficiency) and hypercalcemia (excess calcium) in serum. The characteristic symptom of hypocalcemia is latent or manifest tetany and osteomalacia. Hypocalcemia is due to the absence or impaired function of the parathyroid or impaired vitamin D-synthesis. Hypercalcemia is brought about by increased mobilization of calcium from the skeletal system (osteoporosis) or increased intestinal absorption. The majority of cases are due to primary hyperparathyroidism (pHPT) or bone metastasis of carcinoma of the breast, prostate or thyroid and bronchial carcinoma. The main significance of determining urinary calcium lies in the differentiation between hypercalciuria and hypocalciuria and the differential diagnosis of nephrolithiasis.

PRINCIPLE

Calcium with Arsenazo III at neutral pH yields a Blue Coloured Complex, whose intensity is proportional to the Calcium concentration in the sample. Interference by Magnesium is eliminated by addition of 8-hydroxy quinoline-5-sulphonic acid.

STORAGE AND STABILITY

All the reagents are stable up to the expiry date mentioned on the labels when the proper storage conditions are maintained.

KIT COMPONENTS

1. Calcium Reagent
2. Calcium Standard : Concentration as stated on the label

COMPOSITION

Buffer (50 mmol/l) pH7.2	
8-hydroxy quinoline-5-sulphonic acid	10 mmol/L
Arsenazo III	110 µmol/L
Surfactants and anti oxidants	

REAGENT RECONSTITUTION & STABILITY

Reagent are liquid stable no need for reconstitution. When the reagent is stored properly at RT & the contamination avoided, it is stable up to the expiry date mention on the label & kit box.

MATERIAL REQUIRED BUT NOT PROVIDED

Laboratory Instrumentation, Spectrophotometer UV/VIS with thermostatic cuvette holder or clinical chemistry analyzer: semi auto, calibrated micro pipettes, glass or high quality polystyrene cuvettes, test tube/rack, heating bath controls, saline.

REAGENT DETERIORATION

Discard any turbid reagent if blank reagent absorbance exceeds 1.2 at 630 nm against distilled water.

WARNING & PRECAUTIONS

- Reagent may contain some non reactive and preservative components. It is recommended to handle carefully, avoiding contact with skin and ingestion.
- Specimen should be considered infectious and handled appropriately.
- Contamination by soap or glycerol will affect this assay.
- Perform the test according to the general " Good Laboratory Practice" GLP

SPECIMEN COLLECTION AND STORAGE

1. Fresh Unhemolysed Serum is the preferred specimen.
2. Heparinsed plasma may also be used.
3. Don't use E.D.T.A. plasma.

SYSTEM PARAMETERS:

Reaction type (mode)	:	End Point
Wavelength	:	630nm (600-650)
Flow cell temperature	:	37°C
Sample volume	:	10 µl
Reagent volume	:	1000 µl
Standard concentration	:	10.0
Units	:	mg / dl
Blank	:	Reagent
Low normal	:	8.4
High normal	:	11.5
Linearity	:	25

TEST PROCEDURE

Pipette in to well washed tubes labeled Blank (B), Standard (S) and Test (T) as follows.

Reagent	B	S	T
Arsenazo III Reagent	1.0 ml	1.0 ml	1.0 ml
Calcium Standard (Conc. 10 mg/dl)	----	10 µl	----
Specimen	----	----	10 µl

After adding the specimen/standard close the lid of the vial and mix well. Incubate for 3 minutes at R.T. Read absorbance of Standard (S) and Test (T) against Blank (B) at 630 nm (600-650).

CALCULATIONS

$$\text{Serum calcium in mg/dl} = \frac{\text{Abs. of Test}}{\text{Abs. of Standard}} \times 10$$

EXPECTED VALUES

Serum	adults	8.4 to 11.5 mg/dl
Urine	women	<250 mg/24 hours
	men	<300 mg/24 hours

QUALITY CONTROL & CALIBRATION

It is recommended to perform internal quality control with assayed normal (BioNorm) and assayed abnormal (BioPath), to confirm the validity of the test and assure the accuracy of patient result.

Using the recommended calibrator (Avecon) or the standard included, calibrate the assay:

- When using a new reagent or lot.
- When QC values are out of range.

PERFORMANCE CHARACTERISTICS

1. Linearity

Linearity : 25 mg/dl

2. Sensitivity/ Limit of Detection (LOD)

The lower limit of detection is 0.2 mg/dl

3. Interferences

No significant interference was observed from Bilirubin up to 20 mg/dl (Both conjugated and unconjugated Bilirubin) Hemoglobin up to 50 mg/dl, Lipemia as Triglycerides up to 2000 mg/dl, Ascorbic acid up to 50 mg/dl.

4. Precision:

Intra-Assay

Sample (N=20)	Mean (mg/dl)	SD (mg/dl)	CV%
Control serum 1	8.17	0.13	1.59
Control serum 2	14.88	0.32	2.15
Control serum 3	22.77	0.58	1.95

Inter-Assay

Sample (N=20)	Mean (mg/dl)	SD (mg/dl)	CV%
Control serum 1	8.21	0.14	1.7
Control serum 2	14.92	0.35	2.35
Control serum 3	22.82	0.65	2.84

5. Method Comparison:

A comparison of the LiquiMAX Calcium-SLR (y) with a commercial obtainable assay (x) gave the following result : $y = 1.113x - 0.278$; $r = 0.990$

LIMITATIONS

Measuring range: 0.2-25 mg/dl. Determine samples having higher concentrations manually dilute with 0.9% NaCl or distilled/deionized water (e.g. 1 + 1). Multiply the result by the appropriate dilution factor (e.g. 2).

WASTE DISPOSAL

Reagents must be disposed off in accordance with local regulations.

NOTES














- All glassware and cuvettes should be rinsed with 30% Hydrochloric acid and again rinse with high quality distilled water thoroughly and repeatedly before use.

- If a larger volume of working reagent is required for the absorbance-reading, requisite volumes can be taken in multiples keeping the same ratio of reagent to specimen or standard.
- Dilute lipemic samples with normal saline (made in deionised water) and multiply with dilution factor.
- Protect the kit from direct sunlight.
- For accuracy of results, procedure has to be followed meticulously.
- As with all diagnostic procedures the physician should evaluate data obtained by way of this kit in light of other clinical information.

REFERENCE

- Gitelmen, H.J. (1967) Annal. Biochem 18, 521.
- Berthelot, E.S. (1973) Clin. Chem Acta 46, 46.

Symbols Used on Pack

	Catalogue Number		Warning/Caution
	Batch No.		In vitro diagnostic device
	Manufacturing Date		Storage Limit
	Expiry Date		Consult instruction for use
	Manufacturer		Keep away from sunlight
	Keep Dry		Do not use if package is damaged
	Contains sufficient no. of test		



Manufactured in India by :
AVECON™ Healthcare Pvt. Ltd.
Transforming Research into Innovations